Pfizer’s New Booster Is ‘Substantially’ Better Than Original In Older Adults
Pfizer reports that one month after getting its new bivalent booster, trial participants ages 55 and older had antibody levels almost four times as high as those who received the original booster. But the test group was small, involving just 76 adults, and it's unclear what effect the vaccine will have on a possible winter surge.
CNN:
Pfizer/BioNTech Say Updated Covid-19 Booster Generates 'Substantially Higher' Protection Against Omicron Subvariants Than Original Vaccine
Pfizer and BioNTech said Friday that the immune responses against Omicron BA.4/BA.5 subvariants were “substantially higher” in people who got its new bivalent booster compared with people who received the companies’ original Covid-19 vaccine. (Christensen, 11/4)
The Washington Post:
Pfizer Says New Booster Shot Increases Omicron-Fighting Antibodies
A month after vaccination, the new booster triggered a fourfold increase in omicron-blocking antibody levels against the BA.4/BA.5 version of omicron compared with the old booster in older adults. That is an advantage, but scientists have varying opinions on whether it will make a difference in whether people are likely to fall ill. (Johnson, 11/4)
The New York Times:
Study Shows New Covid Booster Improves Protection For Older People, Pfizer Says
The companies said that one month after getting the new booster, clinical trial participants over 55 had antibody levels that were 3.8 times as high as those who received the original booster. The number of participants in the study was small, with 36 people receiving the new booster and 40 receiving the old one. The control group included only older adults, and the findings so far are limited to one month after the shot. Results from a similar clinical trial by Moderna are expected soon. (LaFraniere, 11/4)
More on the spread of covid —
CNBC:
Fauci: U.S. At Covid Pandemic Crossroads As Omicron Subvariants Emerge
Fauci, in a radio interview Thursday, said the pandemic has clearly eased since last winter, but deaths, which average more than 2,600 per week, remain far too high. At the same time, the new omicron variants are knocking out key tools used to protect the most vulnerable. (Kimball, 11/3)
Los Angeles Times:
Are The Unvaccinated Still A Danger To The Rest Of Us?
“Clearly, the unvaccinated are a threat to themselves,” said Dr. Jeffrey Shaman, an infectious disease specialist at Columbia University. As recently as August, their risk of dying of COVID-19 was six times higher than for people who were fully vaccinated and eight times higher than for people who were vaccinated and boosted, according to the Centers for Disease Control and Prevention. (Healy, 11/3)
CIDRAP:
Report: COVID-19 Likely Spread Through Floors, Walls Of Quarantine Hotel
The Omicron SARS-CoV-2 variant was likely transmitted through the floors and walls of a quarantine hotel in Taiwan in December 2021, adding to a large body of evidence that aerosol transmission plays a significant role in outbreaks and clusters, according to a report yesterday in Emerging Infectious Diseases. (11/3)
Milwaukee Journal Sentinel:
Wisconsin Launches Free Telehealth Program For COVID Antiviral Pills
The state health department launched a new telehealth program Wednesday with the idea of providing Wisconsinites free access to prescription COVID-19 antiviral pills. (Shastri, 11/3)
New Hampshire Public Radio:
N.H. To Launch Telehealth Program For COVID-19 Antiviral Paxlovid
The state is launching a telehealth program to expand access to Paxlovid for New Hampshire residents. The antiviral treatment reduces severe illness among people at high risk from COVID-19. (Cuno-Booth, 11/3)
On treatments for flu and RSV —
ABC News:
Pfizer, BioNTech Launch Phase 1 Trial On Combined COVID-19 And Flu Vaccine
Pfizer and BioNTech have launched a clinical trial on a vaccine targeting both COVID-19 and influenza, the companies announced Thursday. The phase 1 trial is being done in the United States with 180 participants between the ages of 18 and 64, with the first participant dosed this week, the companies said. The follow-up period for each participant will be six months. (Deliso, 11/3)
CNN:
Treatment Approved In Europe To Prevent RSV In Infants Could Be Coming To The US Soon
A preventive treatment for lower respiratory tract infections caused by RSV got the go ahead from the European Commission on Friday, according to one of the companies that make it. The treatment is the first of its kind to protect all infants in their first year of life. (Christensen, 11/4)
